IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
Go back to IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer| (NASDAQ: IMNN) | Delayed: 1.42 +0.04 (2.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.38 | 52 Week High | $ | |||
| Open | $1.40 | 52 Week Low | $ | |||
| Day High | $1.42 | P/E | N/A | |||
| Day Low | $1.38 | EPS | $ | |||
| Volume | 27,556 | |||||
